PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
31.77%
Cash & equivalents yoy growth at least 1.5x AVXL's 5.90%. Mohnish Pabrai might see this as a favorable liquidity edge, provided funds are well deployed.
No Data
No Data available this quarter, please select a different quarter.
31.77%
Cash + STI yoy ≥ 1.5x AVXL's 5.90%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.02%
≥ 1.5x AVXL's 9.21%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
13.80%
Higher PP&E (Net) Growth compared to AVXL's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.28%
Higher Total Non-Current Assets Growth compared to AVXL's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
31.41%
≥ 1.5x AVXL's 9.21%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
2.77%
Above 1.5x AVXL's 0.22%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
1023.68%
Higher Short-Term Debt Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-1.85%
Both AVXL and the company show zero Deferred Revenue (Current) Growth.
No Data
No Data available this quarter, please select a different quarter.
1.86%
Less than half of AVXL's 5.13%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.95%
Higher Total Non-Current Liabilities Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-0.43%
Less than half of AVXL's 5.13%. David Dodd sees far fewer liability expansions relative to competitor.
28.57%
Above 1.5x AVXL's 3.27%. Michael Burry suspects heavy new equity expansion or dilution.
-2.84%
0.5-0.75x AVXL's -3.88%. Martin Whitman is wary of weaker retention or lower profitability.
100.00%
Less than half of AVXL's -100.00%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
34.98%
≥ 1.5x AVXL's 10.35%. David Dodd sees stronger capital base growth than competitor.
31.41%
≥ 1.5x AVXL's 9.21%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
-15.85%
Higher Total Debt Growth compared to AVXL's zero value, indicating worse performance.
-32.66%
Above 1.5x AVXL's -5.90%. Michael Burry sees a major gap in net debt growth. Check coverage and liquidity.